Valeant Pharmaceuticals (VRX) hasn’t missed a beat despite its failed takeover bid for Botox maker Allergan (AGN). Valeant lost out Monday to a competing bid from generic drugmaker Actavis (ACT), which said it would buy Allergan for $66 billion. Yet Valeant climbed 2% in heavy volume that day, clearing a 135.68 buy point from a handle on a long consolidation. It’s now nearly 5% past the buy point, just in buying range.